Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : UBS reiterates its Buy rating

11/25/2020 | 06:06am EST

Already positive, the research from UBS and its analyst Laura Sutcliffe still consider the stock as a Buy opportunity. No major update to the target price set at CHF 98 compared to CHF 99.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -0.60% 83.82 End-of-day quote.0.81%
UBS GROUP AG -1.17% 13.075 End-of-day quote.6.09%
All news about NOVARTIS AG
07:04aNOVARTIS : DZ Bank Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
06:53aNOVARTIS : AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Ad..
MT
04:57aNOVARTIS AG : Credit Suisse reaffirms its Neutral rating
MD
01:32aPRESS RELEASE : Just - Evotec Biologics Expands Contract with the Department of ..
DJ
01/26NOVARTIS : Eyes $4 Billion Sales in China By 2024
MT
01/26NOVARTIS : Places Second in 2021 Access to Medicine Index
MT
01/26Health Care Down After Mixed Earnings -- Health Care Roundup
DJ
01/26Wall Street Wavers Pre-Bell Amid Earnings Deluge
MT
01/26SECTOR UPDATE : Health Care Stocks Gain Pre-Bell Tuesday
MT
01/26US Futures Flat Ahead of Earnings Deluge
MT
More news
Financials (USD)
Sales 2020 49 122 M - -
Net income 2020 8 379 M - -
Net Debt 2020 20 219 M - -
P/E ratio 2020 25,9x
Yield 2020 3,34%
Capitalization 215 B 214 B -
EV / Sales 2020 4,78x
EV / Sales 2021 4,38x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,70 $
Last Close Price 95,07 $
Spread / Highest target 56,6%
Spread / Average Target 15,4%
Spread / Lowest Target -5,08%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.81%214 457
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035
ELI LILLY AND COMPANY25.99%192 848